Haematologica

Chiama Indicazioni Sito Web Contatta la scuola/università

Haematologica www.haematologica.org publishes novel findings in basic, clinical and translational hematology research. Impact Factor (JCR) 7.116 (7th of 76)

Haematologica/The Hematology Journal (pISSN: 0390-6078, eISSN: 1592-8721, NLM ID: 0417435) publishes peer-reviewed papers across all areas of experimental and clinical hematology. The journal is owned by a non-profit organization, the Ferrata Storti Foundation, and serves the scientific community strictly following the International Committee of Medical Journal Editors (ICMJE, www.icmje.org) recommendations on publication ethics policies for medical journals. Haematologica was founded in 1920 by Adolfo Ferrata

Venetoclax has transformed the treatment of acute myeloid leukemia (AML), but resistance and transient responses remain ...
16/10/2026

Venetoclax has transformed the treatment of acute myeloid leukemia (AML), but resistance and transient responses remain major challenges.
A new study explores whether pharmacological inhibition of the Rho/ROCK pathway can enhance venetoclax activity, showing synergistic antileukemic effects across AML cell lines, primary patients’ samples and in vivo models, including venetoclax-resistant disease. The findings provide a preclinical rationale for combining ROCK inhibition with venetoclax in AML.
More details in the comments

Monoclonal proteins can cause thrombosis or bleeding through diverse effects on hemostasis: the ensuing rare entities re...
14/10/2026

Monoclonal proteins can cause thrombosis or bleeding through diverse effects on hemostasis: the ensuing rare entities remain poorly recognized and lack standardized diagnostic and therapeutic approaches. A new Perspective examines monoclonal gammopathy of thrombotic significance and monoclonal gammopathy of bleeding significance, highlighting their heterogeneous mechanisms and the challenges of establishing causality. The authors also discuss an international ISTH initiative aimed at developing a unified framework for their diagnosis and management.
Read the Perspective in Haematologica: “Diagnostic and therapeutic challenges in rare hematologic entities: monoclonal gammopathy of thrombotic and bleeding significance.
More details in the comment

Pain is a major source of morbidity in sickle cell disease (SCD). Current opioid-based strategies may not provide adequa...
12/10/2026

Pain is a major source of morbidity in sickle cell disease (SCD). Current opioid-based strategies may not provide adequate long-term relief but do carry significant risks. A new Review examines emerging preclinical evidence for the use of cannabidiol in SCD, highlighting its potential analgesic and disease-modifying effects through modulation of inflammation, oxidative stress and pain pathways. Although human data remain limited, these findings provide a rationale for further clinical and mechanistic studies.
Read the Review in Haematologica: “Emerging preclinical evidence supports a potential role for cannabidiol in the management of sickle cell disease.”
More details in the comments

Immune checkpoint therapy has transformed the treatment of several lymphomas, but its role in pediatric disease is still...
09/10/2026

Immune checkpoint therapy has transformed the treatment of several lymphomas, but its role in pediatric disease is still evolving. This Review explores the biological rationale and emerging clinical evidence for immune checkpoint therapy across pediatric Hodgkin and non-Hodgkin lymphomas, highlighting where this approach may have the greatest potential.
Read the Review in Haematologica: “Immune checkpoint therapy in pediatric and adolescent lymphomas.”
More details in the comments

Treatment options for relapsed extranodal NK/T-cell lymphoma remain limited, particularly after failure of asparaginase-...
08/10/2026

Treatment options for relapsed extranodal NK/T-cell lymphoma remain limited, particularly after failure of asparaginase-based therapy and immune checkpoint blockade. This Case Report describes a patient with TET2/BCOR-mutant disease who achieved a rapid complete remission after a single cycle of azacitidine, enabling subsequent allogeneic transplantation. The case highlights a potential role for hypomethylating agents in selected relapsed disease and supports further investigation of the biological determinants of response.
More details in the comments

Could the timing of microbial exposure influence the development of childhood acute lymphoblastic leukemia (ALL)? This L...
07/10/2026

Could the timing of microbial exposure influence the development of childhood acute lymphoblastic leukemia (ALL)? This Letter provides experimental evidence that infection-promoted B-cell precursor ALL can arise in genetically susceptible mice following delayed exposure to a microbial environment, whereas early-life exposure appears to be protective. The findings offer further support for a causal role of immune and microbial exposures in childhood ALL and raise questions about possible prevention strategies.
More details in the comments

Inherited chromosomally integrated HHV-6 (eHHV-6) is generally considered a benign genomic trait, but its clinical relev...
28/09/2026

Inherited chromosomally integrated HHV-6 (eHHV-6) is generally considered a benign genomic trait, but its clinical relevance after hematopoietic stem cell transplantation remains debated. In the case reported, eHHV-6A reactivation was associated with systemic manifestations, poor graft function and severely impaired immune reconstitution. Antiviral therapy and stem cell boosting were followed by viral suppression, clinical improvement and recovery of immune function, supporting a pathogenic role for eHHV-6A reactivation after transplantation.
Read the full Case Report in Haematologica.
https://haematologica.org/article/view/14130

What therapeutic options remain for patients with Philadelphia chromosome-positive acute leukemia of ambiguous lineage (...
27/09/2026

What therapeutic options remain for patients with Philadelphia chromosome-positive acute leukemia of ambiguous lineage (Ph⁺ ALAL) who are not candidates for allogeneic transplantation?
A 60-year-old woman with central nervous system involvement obtained a durable deep molecular remission after CD19 CAR T-cell therapy followed by olverembatinib, indicating a potential transplant-free consolidation strategy for this high-risk and challenging disease.
Read the full Case Report in Haematologica.
https://haematologica.org/article/view/14128

What happens when chronic myeloid leukemia (CML) progresses to myeloid blast phase and acquires an unexpected genetic re...
26/09/2026

What happens when chronic myeloid leukemia (CML) progresses to myeloid blast phase and acquires an unexpected genetic rearrangement?
This case report describes the first case of blast-phase CML with a NUP98::HOXC12 fusion, identified through RNA sequencing, representing a previously unrecognized NUP98 fusion partner. The finding expands the spectrum of NUP98 rearrangements and highlights the complex clonal evolution underlying CML progression.
Read the full Case Report in Haematologica.
https://haematologica.org/article/view/14155

Indirizzo

Via Giuseppe Belli 4
Pavia
27100

Orario di apertura

Lunedì 09:00 - 18:00
Martedì 09:00 - 18:00
Mercoledì 09:00 - 18:00
Giovedì 09:00 - 18:00
Venerdì 09:00 - 18:00

Telefono

+39038227129

Sito Web

Notifiche

Lascia la tua email e sarai tra i primi a sapere quando Haematologica pubblica novità e promozioni. Il tuo indirizzo email non verrà utilizzato per nessun altro scopo e potrai annullare l'iscrizione in qualsiasi momento.

Contatta La Scuola/università

Invia un messaggio a Haematologica:

Scelte rapide

Condividi